These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 22723322

  • 21. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [Abstract] [Full Text] [Related]

  • 22. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH.
    Arch Intern Med; 2004 Oct 11; 164(18):2024-30. PubMed ID: 15477438
    [Abstract] [Full Text] [Related]

  • 23. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.
    J Bone Miner Metab; 2014 Jul 11; 32(4):441-6. PubMed ID: 24213216
    [Abstract] [Full Text] [Related]

  • 24. Treatment responses with once-weekly teriparatide therapy for osteoporosis.
    Shiraki M, Ueda S, Sugimoto T, Kuroda T, Nakamura T.
    Osteoporos Int; 2016 Oct 11; 27(10):3057-62. PubMed ID: 27234671
    [Abstract] [Full Text] [Related]

  • 25. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A.
    Clin Calcium; 2012 Mar 11; 22(3):387-98. PubMed ID: 22370306
    [Abstract] [Full Text] [Related]

  • 26. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.
    N Engl J Med; 2007 Nov 15; 357(20):2028-39. PubMed ID: 18003959
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
    Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH.
    Osteoporos Int; 2005 May 15; 16(5):510-6. PubMed ID: 15322742
    [Abstract] [Full Text] [Related]

  • 29. The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk.
    Sone T, Ito M, Fukunaga M, Tomomitsu T, Sugimoto T, Shiraki M, Yoshimura T, Nakamura T.
    Bone; 2014 Jul 15; 64():75-81. PubMed ID: 24727160
    [Abstract] [Full Text] [Related]

  • 30. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.
    Prevrhal S, Krege JH, Chen P, Genant H, Black DM.
    Curr Med Res Opin; 2009 Apr 15; 25(4):921-8. PubMed ID: 19250060
    [Abstract] [Full Text] [Related]

  • 31. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.
    J Bone Miner Res; 2005 Sep 15; 20(9):1507-13. PubMed ID: 16059622
    [Abstract] [Full Text] [Related]

  • 32. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
    Hagino H, Narita R, Yokoyama Y, Watanabe M, Tomomitsu M.
    Osteoporos Int; 2019 Oct 15; 30(10):2027-2037. PubMed ID: 31243480
    [Abstract] [Full Text] [Related]

  • 33. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH.
    Osteoporos Int; 2007 Jan 15; 18(1):59-68. PubMed ID: 17013567
    [Abstract] [Full Text] [Related]

  • 34. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study Group.
    Ann Intern Med; 2007 Mar 06; 146(5):326-39. PubMed ID: 17339618
    [Abstract] [Full Text] [Related]

  • 35. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.
    Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Ozawa T, Takahashi K, Toyone T.
    Spine (Phila Pa 1976); 2012 Nov 01; 37(23):E1464-8. PubMed ID: 22872218
    [Abstract] [Full Text] [Related]

  • 36. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T.
    Osteoporos Int; 2015 Feb 01; 26(2):765-74. PubMed ID: 25403903
    [Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May 01; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 38. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R, Wang O, Satterwhite J, Mitlak B.
    J Bone Miner Res; 2003 Jan 01; 18(1):18-23. PubMed ID: 12510801
    [Abstract] [Full Text] [Related]

  • 39. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
    Crans GG, Silverman SL, Genant HK, Glass EV, Krege JH.
    Arthritis Rheum; 2004 Dec 01; 50(12):4028-34. PubMed ID: 15593198
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 01; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.